Dopamine agonist: Difference between revisions
Brian Blank (talk | contribs) No edit summary |
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
A '''dopamine agonist''' is a compound that activates [[dopamine receptor]]s, mimicking the effect of the neurotransmitter [[dopamine]]. | A '''dopamine agonist''' is a compound that activates [[dopamine receptor]]s, mimicking the effect of the neurotransmitter [[dopamine]]. | ||
| Line 36: | Line 33: | ||
{{Dopamine agonists}} | {{Dopamine agonists}} | ||
{{Receptor agonists and antagonists}} | {{Receptor agonists and antagonists}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 00:52, 9 August 2012
|
WikiDoc Resources for Dopamine agonist |
|
Articles |
|---|
|
Most recent articles on Dopamine agonist Most cited articles on Dopamine agonist |
|
Media |
|
Powerpoint slides on Dopamine agonist |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Dopamine agonist at Clinical Trials.gov Trial results on Dopamine agonist Clinical Trials on Dopamine agonist at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Dopamine agonist NICE Guidance on Dopamine agonist
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Dopamine agonist Discussion groups on Dopamine agonist Patient Handouts on Dopamine agonist Directions to Hospitals Treating Dopamine agonist Risk calculators and risk factors for Dopamine agonist
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Dopamine agonist |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
A dopamine agonist is a compound that activates dopamine receptors, mimicking the effect of the neurotransmitter dopamine.
Uses
Some medical drugs act as dopamine agonists; they are typically used for treating Parkinson's disease, and may be useful for restless legs syndrome (RLS). Both Requip (Ropinirole) and Mirapex (Pramipexole) are FDA approved for the treatment of RLS.
There is also an ongoing clinical trial to test the effectiveness of Requip (Ropinirole), a dopamine agonist, in reversing the symptoms of SSRI induced sexual dysfunction. [1]
Examples
Examples of dopamine agonists include:
- Parlodel (bromocriptine)
- Permax (Pergolide) - Removed from market March 29,2007.[2]
- Mirapex (Pramipexole)
- Requip (Ropinirole)
- Apokyn (apomorphine)
See also
References
- ↑ Clinical trial number NCT00334048 at ClinicalTrials.gov - "Treating Sexual Dysfunction From SSRI Medication: a Study Comparing Requip CR to Placebo"
- ↑ http://www.fda.gov/bbs/topics/NEWS/2007/NEW01596.html
External links
- Dopamine+Agonists at the US National Library of Medicine Medical Subject Headings (MeSH)
Template:Dopamine agonists Template:Receptor agonists and antagonists